MWNA
FNCH

Marshall Wace North America’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Marshall Wace North America’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,578
Closed -$753K – 1894
2021
Q1 		$753K Buy
+1,578
New +$804K ﹤0.01% 1111

Other funds holding FNCH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
TA
TRB Advisors New York $146M AUM 3.71% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace North America's FNCH Position: Q2 2021 in Review

Marshall Wace North America sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2021, closing a stake of 1,578 shares — an estimated $753K sold.

Marshall Wace North America first reported a position in FNCH in Q1 2021 and held it in 1 quarter. The position peaked at $753K in Q1 2021. 45 funds tracked by Wall St. Rank hold FNCH as of Q2 2021.

  • Marshall Wace North America reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 1,578 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2021, an estimated $753K.
  • Marshall Wace North America first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Marshall Wace North America's Finch Therapeutics Group, Inc. Common Stock position peaked at $753K in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.